3.5.4.5	(cytidyl)acryloylaminohexanoic acid	i.e. CV6	35854	
3.5.4.5	1,10-phenanthroline	-	62	
3.5.4.5	1-(beta-D-ribofuranosyl)-2-pyrimidone	-	21436	
3.5.4.5	1-(beta-D-ribofuranosyl)-dihydropyrimidine-2-one	zebularine	21437	
3.5.4.5	1-(beta-D-ribofuranosyl)-dihydropyrimidine-2-one	-	21437	
3.5.4.5	1-methyladenosine	competitive inhibition	10464	
3.5.4.5	2'-deoxyuridine	-	1705	
3.5.4.5	2'-deoxyzebularine 5'-monophosphate	-	104402	
3.5.4.5	2-beta-D-ribofuranosyl-1,2,4-triazol-3-one	-	104515	
3.5.4.5	2-mercaptoethanol	-	63	
3.5.4.5	2-thio-6-azarudine	-	104656	
3.5.4.5	3'-azido-3'-deoxythymidine	-	1185	
3.5.4.5	3,4,5,6,tetrahydrozebularine	-	48569	
3.5.4.5	3,4,5,6-Tetrahydrouridine	potent competitive inhibitor	2933	
3.5.4.5	3,4,5,6-Tetrahydrouridine	-	2933	
3.5.4.5	3,4,5,6-Tetrahydrouridine	recombinant CDA	2933	
3.5.4.5	3,4,5,6-Tetrahydrouridine	i.e. THU	2933	
3.5.4.5	3,4-dihydrouridine	-	48571	
3.5.4.5	3,4-dihydrozebularine	-	48575	
3.5.4.5	3-deazauridine	-	12336	
3.5.4.5	3-deazauridine	recombinant enzyme	12336	
3.5.4.5	4-amino-1-(5-hydroxypentyl)pyrimidin-2(1H)-one	-	105756	
3.5.4.5	4-amino-1-hexyl-5,6-dihydropyrimidin-2(1H)-one	-	105755	
3.5.4.5	4-hydroxy-1-(beta-D-ribofuranosyl)piperidin-2-one	-	105754	
3.5.4.5	5,6-Dihydrouridine	competitive inhibition	4769	
3.5.4.5	5,6-Dihydrouridine	-	4769	
3.5.4.5	5-(Chloromercuri)cytidine	-	20034	
3.5.4.5	5-bromodeoxyuridine	-	3317	
3.5.4.5	5-bromodeoxyuridine	1.0 mM, 31% inhibition	3317	
3.5.4.5	5-Bromouridine	-	4215	
3.5.4.5	5-fluoro-2'-deoxyuridine	-	3318	
3.5.4.5	5-fluoro-2'-deoxyuridine	recombinant enzyme	3318	
3.5.4.5	5-fluoropyrimidin-2-one ribonucleoside	-	105119	
3.5.4.5	5-fluorouridine	-	2938	
3.5.4.5	5-fluorozebularine	-	5302	
3.5.4.5	5-iodo-2'-deoxyuridine	-	6124	
3.5.4.5	5-methyluridine	-	3184	
3.5.4.5	5-{(1E)-3-[(5-carboxypentyl)amino]-3-oxoprop-1-en-1-yl}-5,6-dihydrocytidine	-	32183	
3.5.4.5	5-{(1E)-3-[(5-carboxypentyl)amino]-3-oxoprop-1-en-1-yl}-5,6-dihydrocytidine	recombinant enzyme	32183	
3.5.4.5	6-azauridine	-	2133	
3.5.4.5	6-thioguanine	-	1253	
3.5.4.5	6-[3-(5-cytidyl)acryloylamino]hexanoic acid	i.e. CV6	37848	
3.5.4.5	acetone	-	333	
3.5.4.5	adenosine	4.0 mM, 22% inhibition	122	
3.5.4.5	adenosine	-	122	
3.5.4.5	Ag+	-	75	
3.5.4.5	ara-U	-	105467	
3.5.4.5	blasticidin S	-	3195	
3.5.4.5	Borate	-	1395	
3.5.4.5	CDP	-	212	
3.5.4.5	CMP	0.300 mM 50% inhibition, 0.750 mM 90% inhibition	100	
3.5.4.5	CMP	-	100	
3.5.4.5	CMP	recombinant CDA	100	
3.5.4.5	CTP	-	60	
3.5.4.5	Cu2+	-	19	
3.5.4.5	CuSO4	complete inhibition	263	
3.5.4.5	cytidine	strong substrate inhibition above 0.5 mM	372	
3.5.4.5	cytidine monophosphate	-	24116	
3.5.4.5	dCMP	-	450	
3.5.4.5	deoxyadenosine	3.0 mM, 32% inhibition	601	
3.5.4.5	deoxyadenosine	competitive inhibition	601	
3.5.4.5	deoxyadenosine	-	601	
3.5.4.5	deoxyguanosine	1.0 mM, 13% inhibition	732	
3.5.4.5	deoxyguanosine	-	732	
3.5.4.5	deoxyuridine	-	1060	
3.5.4.5	deoxyuridine	1.0 mM, 32% inhibition	1060	
3.5.4.5	deoxyuridine	competitive inhibition	1060	
3.5.4.5	diazepinone riboside	-	32200	
3.5.4.5	diazepinone riboside	inhibitor is able to establish a canonical pi/pi interaction with key active site residue F137	32200	
3.5.4.5	dihydrothymidine	competitive inhibition	32203	
3.5.4.5	dipicolinic acid	-	1443	
3.5.4.5	dithiothreitol	-	45	
3.5.4.5	dTMP	0.400 mM 50% inhibition	635	
3.5.4.5	DTNB	-	554	
3.5.4.5	dTTP	-	145	
3.5.4.5	dTTP	0.400 mM 50% inhibition	145	
3.5.4.5	dUTP	-	435	
3.5.4.5	EDTA	-	21	
3.5.4.5	Fe2+	-	25	
3.5.4.5	Fe3+	-	70	
3.5.4.5	GTP	0.750 mM 85% inhibition	37	
3.5.4.5	guanosine	1.0 mM, 4% inhibition	296	
3.5.4.5	guanosine	-	296	
3.5.4.5	Hg+	-	1756	
3.5.4.5	HgCl2	complete inhibition	110	
3.5.4.5	mercaptoethanol	-	1623	
3.5.4.5	Mersalyl acid	-	3084	
3.5.4.5	N-ethylmaleimide	-	49	
3.5.4.5	N-ethylmaleimide	weak inhibition	49	
3.5.4.5	NH3	product inhibition	27	
3.5.4.5	NH3	-	27	
3.5.4.5	p-chloromercuribenzoate	-	43	
3.5.4.5	p-mercuribenzoate	highly sensitive	686	
3.5.4.5	p-mercuribenzoate	-	686	
3.5.4.5	p-mercuribenzoate	enzyme from leukemic spleen, enzyme from normal spleen is much less sensitive	686	
3.5.4.5	phosphapyrimidine	-	107056	
3.5.4.5	phosphapyrimidine nucleoside	-	107057	
3.5.4.5	pseudouridine	-	7276	
3.5.4.5	SDS	wild-type tetramer dissociates into enzymatically inactive monomers, without intermediate forms via a non-cooperative transition. Extensive dialysis or dilution of the inativated monomers restores completely the activity. 5-Fluorozebularine disfavours dissociation of the tetramer into subunits in the wild-type enzyme, but not in the mutant enzyme F137W/W113F	124	
3.5.4.5	tetrahydrouridine	-	13414	
3.5.4.5	tetrahydrouridine	i.e. THU, acts as as a transition-state analogue of the natural substrate cytidine, quantitative determination of the cytidine deaminase inhibitor in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry, pharmacokinetics, overview	13414	
3.5.4.5	tetrahydrouridine	THU, the presence of 1 microM totally prevents the formation of 5'-deoxy-5-fluorouridine in blood samples of healthy volunteers and capecitabine-treated patients	13414	
3.5.4.5	thioglycolic acid	0.7 mM 88% relative activity, complete inhibition at 7 mM	2360	
3.5.4.5	thymidine	1.0 mM, 21% inhibition	166	
3.5.4.5	thymidine	competitive inhibition	166	
3.5.4.5	thymidine	-	166	
3.5.4.5	thymine riboside	competitive inhibition	11161	
3.5.4.5	thymine riboside	-	11161	
3.5.4.5	thymine riboside	recombinant CDA	11161	
3.5.4.5	uracil arabinoside	4.0 mM, 48% inhibition	20565	
3.5.4.5	Urea	above 2 M, reversible inactivation	116	
3.5.4.5	uridine	-	261	
3.5.4.5	uridine	product inhibition	261	
3.5.4.5	uridine	4.0 mM, 20% inhibition	261	
3.5.4.5	uridine	inhibition relatively slow	261	
3.5.4.5	uridine	recombinant enzyme	261	
3.5.4.5	UTP	-	65	
3.5.4.5	UTP	recombinant CDA	65	
3.5.4.5	zebularine	inhibits the enzyme, but also DNA methylation, competitive versus 5-aza-2'-deoxycytidine, zebularine affects the antineoplastic action of 5-AZA-CdR on 3T3 cells and V5 cells transduced with CR deaminase gene, overview	6183	
3.5.4.5	Zn2+	above 10 mM	14